LEADER 00891nam0-22002891i-450- 001 990007673220403321 035 $a000767322 035 $aFED01000767322 035 $a(Aleph)000767322FED01 035 $a000767322 100 $a20021010d--------km-y0itay50------ba 101 0 $aita 200 1 $aC.I.P.A. guide to the Patents Act 1977 Texts$ecommentary and notes on pratice 205 $a2. ed. 210 $aLondon$cSweet & MaxWell$d1984 215 $aLIII, 772 + supp. p.$d24 cm 300 $aContiene : First Cumulative Supplement up to date February 1, 1984. 676 $a346.07 710 02$aCHARTERED INSTITUTE OF PATENT AGENTS$0277004 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007673220403321 952 $a12-B-45$b4376$fDDCP 959 $aDDCP 996 $aC.I.P.A. guide to the Patents Act 1977 Texts$9680146 997 $aUNINA DB $aGEN01 LEADER 10646nam 2200577 450 001 9910506389503321 005 20230329150828.0 010 $a3-030-85026-9 035 $a(CKB)4950000000280558 035 $a(MiAaPQ)EBC6788041 035 $a(Au-PeEL)EBL6788041 035 $a(OCoLC)1280276432 035 $a(PPN)258303158 035 $a(EXLCZ)994950000000280558 100 $a20220712d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEssentials of aerosol therapy in critically ill patients /$fHaitham Saeed [and three others] 210 1$aCham, Switzerland :$cSpringer,$d[2021] 210 4$d©2021 215 $a1 online resource (245 pages) 311 $a3-030-85025-0 320 $aIncludes bibliographical references and index. 327 $aIntro -- Preface -- Contents -- Abbreviations -- Chapter 1: The Type of Patients Requiring Aerosol Therapy (to Treat What and Where?) -- 1.1 Introduction -- 1.2 Differences Between Pediatrics and Adults Influencing Aerosol Delivery -- 1.3 Diseases Treated by Aerosol Therapy -- 1.3.1 Asthma -- 1.3.1.1 Asthma Diagnosis -- 1.3.1.2 Asthma Phenotypes -- 1.3.1.3 Asthma Management -- Non-pharmacological Treatment -- Pharmacological Treatment -- 1.3.1.4 Asthma Exacerbations -- Prevention of Exacerbations -- Management of Asthma Exacerbations -- 1.3.2 Chronic Obstructive Pulmonary Disease -- 1.3.2.1 COPD Diagnosis -- 1.3.2.2 Differences Between COPD and Asthma Diagnosis -- 1.3.2.3 Management of Stable COPD -- 1.3.2.4 Management of COPD Exacerbations -- References -- Chapter 2: Types of Mechanical Ventilation -- 2.1 Mechanical Ventilation -- 2.2 Non-invasive Ventilation -- 2.3 Non-invasive Negative Pressure Ventilation -- 2.4 Non-invasive Positive Pressure Ventilation -- 2.5 Ventilation Modes -- 2.6 Configuration of NIV Circuit -- 2.7 Invasive Ventilation -- 2.8 Endotracheal Intubation -- 2.9 Tracheostomy -- 2.10 Complications of Mechanical Ventilation -- 2.11 Acute Respiratory Distress Syndrome (ARDS) -- 2.12 Ventilator-Associated Pneumonia (VAP) -- 2.13 Pneumothorax -- 2.14 Atelectasis -- 2.15 Pulmonary Edema -- 2.16 Pleural Effusion -- References -- Chapter 3: Oxygen Delivery Systems and Nasally Ventilated Patients -- 3.1 Introduction -- 3.2 Oxygen Device -- 3.3 Clinical Benefits Offered by HFNC -- 3.3.1 Improvement of Mucociliary Clearance -- 3.3.2 Anatomical Dead Space Washout -- 3.3.3 Positive End-Expiratory Pressure (PEEP) Effect -- 3.3.4 Provision of the Stable Fraction of Inspired Oxygen -- 3.4 Attenuation of Inspiratory Resistance (Work of Breathing) -- 3.4.1 By Providing Adequate Flow -- 3.4.2 By Supplying Adequately Heated and Humidified Gas. 327 $a3.4.2.1 Potential Clinical HFNC Applications -- 3.5 Obstructive Airways Diseases -- 3.6 Hypoxemic Respiratory Failure -- 3.7 Hypercapnic Respiratory Failure -- 3.8 Acute Cardiogenic Pulmonary Edema (ACPE) -- 3.9 Respiratory Infection -- 3.10 Post-extubation -- 3.11 Do-Not-Intubate Patients and Palliative Care -- 3.12 Home Oxygen Therapy or Long Term Oxygen Therapy (LTOT) -- 3.13 Oxygen Concentrators -- 3.14 Compressed Gas Cylinders -- 3.15 Liquid Oxygen Systems -- References -- Chapter 4: Special Needs for Neonates, Infants, and Toddler -- 4.1 Introduction -- 4.2 Differences Between Pediatric and Adult Patients in the Delivery of Inhaled Medications -- 4.3 Age Is a Factor for Choosing the Best Aerosol-Generating Device -- 4.4 Patient-Related Factors -- 4.5 Selection of Aerosol-Generating Devices -- 4.6 Aerosol Generating Devices -- 4.7 Nebulizers -- 4.7.1 Jet Nebulizer -- 4.7.2 Ultrasonic Nebulizers -- 4.7.3 Vibrating Mesh Nebulizers -- 4.8 Pressurized Metered-Dose Inhalers -- 4.9 Dry Powder Inhalers -- 4.10 Selection of Aerosol Therapy Interface -- 4.11 Valved Holding Chamber and Spacers -- References -- Chapter 5: Transitioning Aerosol from Hospital to Home -- Role of Training and Follow-Up -- 5.1 Challenges of Aerosol Therapy -- 5.2 Factors Affecting Adherence to Aerosol Therapy -- 5.2.1 The Aerosol Generating Devices -- 5.2.2 Drug-Related Factors -- 5.2.3 Healthcare Professional Related Factors -- 5.3 Factors Related to the Patient -- 5.4 Role of Counseling in Patient Adherence -- 5.4.1 Counseling Sessions -- 5.5 Patient Preference-Based Inhaler Selection -- 5.5.1 Inhaler Labeling -- 5.5.2 Aerosol Therapies Follow Up -- 5.5.3 Evaluation of Patient Inhaler Usage Technique -- 5.5.4 Inhalation Manager -- 5.5.5 Aerosol Inhalations Monitor (AIM) -- 5.5.6 Mag-Flo Inhaler -- 5.5.7 Turbutest -- 5.5.8 2Tone Trainer -- 5.5.9 In-Check DIAL. 327 $a5.5.10 Trainhaler and Flo-Tone -- 5.5.11 Clip-Tone E -- 5.6 Monitoring Patient Adherence to Aerosol Therapy -- 5.7 Clinical Judgment on Therapy -- 5.8 Self-Reports by Patients -- 5.9 Electronic Monitoring Device -- 5.10 Laboratory Measurements of Medications and Response -- 5.11 Pharmacy Registered Data -- 5.12 Assessment Tools for Aerosol Therapy and Disease Control -- 5.12.1 Questionnaires in Asthma -- 5.12.2 Asthma Control Questionnaire -- 5.12.3 Asthma Control Test -- 5.12.4 Asthma Therapy Assessment Questionnaire (ATAQ) -- 5.12.5 Test for Respiratory and Asthma Control in Kids -- 5.12.6 Questionnaires for Assessment of COPD -- References -- Chapter 6: The Aerosol Generators Available for Critically Ill Patient -- 6.1 Introduction -- 6.2 Discussion and Analysis of Main Topics -- 6.2.1 Nebulizers -- 6.2.1.1 Air-Jet Nebulizer (JNs) -- 6.2.1.2 Ultrasonic Nebulizers (USNs) -- 6.2.1.3 Vibrating Mesh Nebulizer (VMNs) -- 6.2.2 Pressurized Metered Dose Inhalers (pMDIs) -- 6.2.2.1 Add-on Devices (Spacers) -- 6.2.3 Dry Powder Inhalers (DPIs) -- 6.2.4 Soft Mist Inhalers (SMIs) -- 6.3 Conclusion -- References -- Chapter 7: Mechanisms of Aerosol Lung Deposition -- 7.1 Principles of Aerosol Delivery -- 7.2 Physical Principles that Control Aerosol Delivery and Deposition -- 7.2.1 Particle Size -- 7.2.2 Inertial Impaction -- 7.2.3 Gravitational Sedimentation -- 7.2.4 Brownian Motion and Diffusion -- 7.2.5 Electrostatic Attraction -- 7.2.6 Variables Related to the Patient -- 7.2.7 Deposition in the Oropharyngeal Regions -- 7.3 Oral Deposition for the Dry Powder Inhalers (DPIs) -- 7.3.1 Lung Clearance Mechanisms -- 7.3.2 The Optimal Site for Aerosol Therapy Deposition for Management of Lung Diseases -- 7.4 Optimal Site of Aerosol Therapy Deposition for Management of Systemic Diseases -- References. 327 $aChapter 8: Factors Affecting Aerosol Deposition in Critically Ill Patient -- 8.1 Introduction -- 8.2 Discussion and Analysis of Main Topics -- 8.2.1 Ventilator-Related Factors -- 8.2.2 Circuit-Related Factors -- 8.2.3 Device-Related Factors -- 8.2.4 Drug-Related Factors -- 8.2.5 Patient-Related Factors -- 8.3 Conclusion -- References -- Chapter 9: Inhaled Medications Employed in Critically Ill Patients -- 9.1 Introduction -- 9.2 Discussion and Analysis of Main Topics -- 9.2.1 Inhaled Medications Employed During Mechanical Ventilation (MV) -- 9.2.1.1 Bronchodilators -- 9.2.1.2 Prostanoids -- 9.2.1.3 Surfactant -- 9.2.1.4 Antibiotics/Antibacterial -- 9.2.1.5 Antiviral -- 9.2.1.6 Mucolytic Agents -- 9.2.1.7 Corticosteroids -- 9.2.1.8 Miscellaneous -- 9.2.2 Common Applications of Aerosol Therapy in Critical Care -- 9.2.3 Effect of Dosing -- 9.2.4 Effect of Administration Technique -- 9.2.5 Limitations of Aerosol Therapy in Critical Care -- 9.3 Conclusion -- References -- Chapter 10: Aerosol Therapies During High Flow Oxygen Therapy -- 10.1 Introduction -- 10.2 Factors Affecting Aerosol Delivery Within High Flow Oxygen System -- 10.2.1 Flow Rate of Gas -- 10.2.2 The Type of Aerosol Generator and Its Position Within the HFNC Circuit -- 10.2.3 Density of Gas -- 10.2.4 Interface -- References -- Chapter 11: Methods of Detecting Aerosol Delivery to the Lung -- 11.1 Introduction -- 11.2 Particle Size Distribution -- 11.3 Measuring Aerosol Particle Distribution with Inertial Impaction -- 11.4 Twin Stage Impinger -- 11.5 Marple-Miller Cascade Impactor -- 11.6 Multistage Liquid Impinger -- 11.7 Anderson Cascade Impactor -- 11.8 Next-Generation Impactors -- 11.9 Light Diffraction Methods -- 11.10 Laser Diffraction -- 11.11 Pulmonary Function Tests -- 11.12 Spirometry -- 11.13 Models Used for Aerosol Delivery Quantification -- 11.14 In-Vitro Models. 327 $a11.15 In-Vitro Determination of Emitted Dose -- 11.16 In-Vitro Model for Characterization of Aerosol Particle Size Via Inertial Impaction -- 11.16.1 In-Vivo Models -- 11.16.2 Pharmacokinetics Model -- 11.16.3 Ex-Vivo Models -- 11.16.4 Imaging Models -- 11.16.5 Data Modeling -- References -- Chapter 12: Monitoring Plans and Weaning Protocols for Critically Ill Patients -- 12.1 Introduction -- 12.2 Discussion and Analysis of Main Topics -- 12.2.1 Monitoring Patient During Invasive Mechanical Ventilation (IMV) -- 12.2.1.1 Monitoring of Ventilator Parameters During IMV -- 12.2.1.2 Monitoring Spontaneous Breathing During IMV -- Monitoring through Esophageal Pressure (Pes) -- Transpulmonary Pressure (PL) -- Inspiratory Muscle Pressure (Pmus) -- Transdiaphragmatic Pressure (Pdi) -- Monitoring Through Occlusion Maneuvers -- Inspiratory Occlusion Maneuver -- Expiratory Occlusion Maneuver -- Airway Occlusion Pressure (P0.1) -- Monitoring Through Electrical Activity of the Diaphragm (EAdi) -- Monitoring Through Diaphragm Ultrasound -- 12.2.1.3 Monitoring of ETT -- 12.2.1.4 Monitoring of TST -- 12.2.2 Weaning from IMV -- 12.2.3 Monitoring of Patient During NIV -- 12.2.3.1 Monitoring of Clinical Parameters During NIV -- 12.2.3.2 Monitoring of Special Laboratory Indices during NIV -- 12.2.3.3 Monitoring of Lung Functions and Ventilator Parameters During NIV -- 12.2.4 Optimizing Ventilator Settings During NIV -- 12.2.5 Weaning from NIV -- 12.3 Conclusion -- References. 606 $aAerosol therapy 606 $aCritical care medicine 606 $aInternal medicine 606 $aAerosolteràpia$2thub 606 $aMedicina intensiva$2thub 608 $aLlibres electrònics$2thub 615 0$aAerosol therapy. 615 0$aCritical care medicine. 615 0$aInternal medicine. 615 7$aAerosolteràpia. 615 7$aMedicina intensiva 676 $a615.836 700 $aSaeed$b Haitham$01072131 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910506389503321 996 $aEssentials of Aerosol Therapy in Critically Ill Patients$92568273 997 $aUNINA LEADER 03425cam a2200373 i 4500 001 991003234729707536 008 070802s2006 ne a sb 001 0 eng d 020 $a9780123693907 020 $a012369390X 035 $ab13652904-39ule_inst 040 $aBibl. Dip.le Aggr. Ingegneria Innovazione - Sez. Ingegneria Innovazione$beng 082 04$a617.56$222 100 1 $aKurtz, Steven M.,$d1968-$0627359 245 10$aSpine technology handbook$h[e-book] /$cSteven M. Kurtz, Avram Allan Edidin 260 $aAmsterdam ;$aBoston :$bElsevier Academic Press,$cc2006 300 $axiv, 535 p. :$bill. (some col.) ;$c25 cm 504 $aIncludes bibliographical references and index 505 0 $aOverview of Spine; Intro to Properties of Materials and Synthetic Biomaterials Used in the Spine; Structure & Properties of Soft Tissues in the Spine; Structure & Properties of Trabecular Bone in the Spine; Muscular Actuation and Biomechanics of the Spine; Spine Disorders: Implications for Bioengineers; Fusion: Rods, Plates, Screws, and Cages; Performance of Rods, Plates, Screws and Cages; Biologics to Promote Spine Fusion; Disc Repair & Augmentation; Total Disc Replacement; Vertebral Compression Fracture Augmentation; Standard Test Methods for Spine Implants; Advanced Finite Element Analysis in Preclinical Assessment of Spine Technology; Regulatory Approval Process. 520 $aOver the past decade, there has been rapid growth in bioengineering applications in the field of spine implants. This book explains the technical foundation for understanding and expanding the field of spine implants, reviews the major established technologies related to spine implants, and provides reference material for developing and commercializing new spine implants. The editors, who have a track record of collaboration and editing technical books, provide a unified approach to this topic in the most comprehensive and useful book to date. Related website provides the latest information on spine technology including articles and research papers on the latest technology and development. Major technologies reviewed include devices used for fusion (screws, plates, rods, and cages), disc repair and augmentation, total disc replacement, and vertebral body repair and augmentation. Technology landscape, review of published/public domain data currently available, and safety and efficacy of technology discussed in detail 533 $aElectronic reproduction.$bAmsterdam :$cElsevier Science & Technology,$d2007.$nMode of access: World Wide Web.$nSystem requirements: Web browser.$nTitle from title screen (viewed on July 25, 2007).$nAccess may be restricted to users at subscribing institutions 650 0$aSpine 650 0$aSpine$xMechanical properties 650 0$aSpine$xSurgery 650 0$aSpinal implants 650 0$aBiomedical engineering 655 7$aElectronic books.$2local 700 1 $aEdidin, Avram Allan$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0738997 776 1 $cOriginal$z012369390X$z9780123693907$w(OCoLC)71252810 856 40$3Referex$uhttp://www.sciencedirect.com/science/book/9780123693907$zAn electronic book accessible through the World Wide Web; click for information 907 $a.b13652904$b03-03-22$c24-01-08 912 $a991003234729707536 996 $aSpine technology handbook$91463935 997 $aUNISALENTO 998 $ale026$b24-01-08$cm$d@ $e-$feng$gne $h0$i0